Evidence map›Paper›PMID 39097214›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2024

Extended survival of 9- and 10-gene-edited pig heart xenografts with ischemia minimization and CD154 costimulation blockade-based immunosuppression.

Ryan Chaban, Ikechukwu Ileka, Gannon McGrath, Kohei Kinoshita, Zahra Habibabady, Madelyn Ma, Victoria Diaz, Akihiro Maenaka, Anthony Calhoun, Megan Dufault and 16 more

Abstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Contributions of Europeans to Xenotransplantation Research: 1. Pig Organ Xenotransplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  3. Review
  4. What Genetic Modifications of Source Pigs Are Essential and Sufficient for Cell, Tissue, and Organ Xenotransplantation?Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ryan ChabanCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Department of Cardiovascular Surgery, University Hospital of Mainz, Mainz, Germany.
Ikechukwu IlekaCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Gannon McGrathCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Kohei KinoshitaCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Zahra HabibabadyCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Madelyn MaCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Victoria DiazCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Akihiro MaenakaCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Anthony CalhounCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Megan DufaultCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Ivy RosalesCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Christiana M LaguerreCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Seyed-Amir SanatkarCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Lars BurdorfCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Revivicor, Inc., Blacksburg, Virginia.
David L AyaresRevivicor, Inc., Blacksburg, Virginia.
William EyestoneRevivicor, Inc., Blacksburg, Virginia.
Prachi SardanaRevivicor, Inc., Blacksburg, Virginia.
Kasinath KuraviRevivicor, Inc., Blacksburg, Virginia.
Lori SorrellsRevivicor, Inc., Blacksburg, Virginia.
Seth LedermanTonix Pharma LLC, Chatham, New Jersey.
Caroline G LucasNational Swine Resource and Research Center (NSRRC), Animal Science Research Center, University of Missouri, Columbia, Missouri.
Randall S PratherNational Swine Resource and Research Center (NSRRC), Animal Science Research Center, University of Missouri, Columbia, Missouri.
Kevin D WellsNational Swine Resource and Research Center (NSRRC), Animal Science Research Center, University of Missouri, Columbia, Missouri.
Kristin M WhitworthNational Swine Resource and Research Center (NSRRC), Animal Science Research Center, University of Missouri, Columbia, Missouri.
David K C CooperCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Richard N PiersonCenter for Transplantation Sciences and Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: rpierson@mgh.harvard.edu.

Funding

Resource Core for National Swine Resource and Research Center (NSRRC) Years 21-25U42OD011140 · OD · UNIVERSITY OF MISSOURI-COLUMBIA · PI Kiho Lee · 2012 to 2026
$26.7M
Prolonging life-supported pig kidney and heart graft survival in baboons by suppressing inflammationU19AI090959 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2010 to 2024
$26.3M
TRAINING IN TRANSPLANTATION BIOLOGYT32AI007529 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 1998 to 2024
$6.4M
CRISPR-Modified Cardiac Xenograft TransplantationU01AI153612 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI PIERSON, RICHARD N · 2021 to 2024
$3.2M
Liver Xenotransplantation using CRISPR-modified Porcine OrgansU01AI146248 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI MARKMANN, JAMES FRANCIS · 2021 to 2024
$3.0M
CRISPR-Modified Cardiac Xenograft TransplantationR01AI153612 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI PIERSON, RICHARD N · 2020 to 2020
$796k
Liver Xenotransplantation using CRISPR-modified Porcine OrgansR01AI146248 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARKMANN, JAMES FRANCIS · 2020 to 2020
$772k
NIAID NIH HHS R01 AI146248NIAID NIH HHS R01 AI153612NIAID NIH HHS T32 AI007529NIAID NIH HHS U01 AI146248NIAID NIH HHS U01 AI153612NIAID NIH HHS U19 AI090959NIH HHS U42 OD011140
6 · The paper itself

Abstract

backgroundXenotransplantation has made significant advances recently using pigs genetically engineered to remove carbohydrate antigens, either alone or with addition of various human complement, coagulation, and anti-inflammatory ''transgenes''. Here we evaluated results associated with gene-edited (GE) pig hearts transplanted in baboons using an established costimulation-based immunosuppressive regimen and a cold-perfused graft preservation technique.

methodsEight baboons received heterotopic abdominal heart transplants from 3-GE (GalKO.β4GalNT2KO.hCD55, n = 3), 9-GE (GalKO.β4GalNT2KO.GHRKO.hCD46.hCD55. TBM.EPCR.hCD47. HO-1, n = 3) or 10-G (9-GE+CMAHKO, n = 2) pigs using Steen's cold continuous perfusion for ischemia minimization. Immunosuppression (IS) included induction with anti-thymocyte globulin and αCD20, ongoing αCD154, MMF, and tapered corticosteroid.

resultsAll three 3-GE grafts functioned well initially, but failed within 5 days. One 9-GE graft was lost intraoperatively due to a technical issue and another was lost at POD 13 due to antibody mediated rejection (AMR) in a baboon with a strongly positive pre-operative cross-match. One 10-GE heart failed at POD113 with combined cellular and antibody mediated rejection. One 9-GE and one 10-GE hearts had preserved graft function with normal myocardium on protocol biopsies, but exhibited slowly progressive graft hypertrophy until elective necropsy at POD393 and 243 respectively. Elevated levels of IL-6, MCP-1, C-reactive protein, and human thrombomodulin were variably associated with conditioning, the transplant procedure, and clinically significant postoperative events.

conclusionRelative to reference genetics without thrombo-regulatory and anti-inflammatory gene expression, 9- or 10-GE pig hearts exhibit promising performance in the context of a clinically applicable regimen including ischemia minimization and αCD154-based IS, justifying further evaluation in an orthotopic model.

Indexed as

CD40 LigandGraft SurvivalHeart TransplantationImmunosuppression TherapyPapioAnimalsAnimals, Genetically ModifiedGene EditingGraft RejectionHeterograftsSwineTransplantation, HeterologousCD40 Ligandcostimulation pathway blockadegenetic engineeringheart transplantationswinexenotransplantation

Identifiers

PMID39097214
PMCPMC11568940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.